A phase 3 clinical trial of T-VEC demonstrated partial and complete responses at both injected and noninjected sites in patients with stage 3 or 4 disease (16.3%) compared with GM-CSF alone (2.1%).4 Before this, in 2005, H101 (Oncorine) was approved for the treatment of patients with late-stage refractory nasopharyngeal cancer in China.9 Oncorine (H101) is a recombinant human serotype-5 adenovirus (Ad5) with the E1B gene deleted, which leads to p53 inactivation and subsequently, viral replication. The gene discussed is TP53; the disease is nasopharyngeal carcinoma.